<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9876">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02978378</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00006088</org_study_id>
    <nct_id>NCT02978378</nct_id>
  </id_info>
  <brief_title>Renal Biomarkers to Predict Recovery Following Venoarterial Extracorporeal Membrane Oxygenation</brief_title>
  <official_title>Renal Biomarkers to Predict Recovery Following Venoarterial Extracorporeal Membrane Oxygenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators objective is to assess the utility of renal biomarkers in predicting renal
      recovery following institution of Venoarterial Extracorporeal Membrane Oxygenation
      (VA-ECMO). Tissue biomarkers of renal injury may provide a real-time indication of renal
      function and the likelihood of renal recovery in patients having cardiogenic shock and
      requiring VA-ECMO. In these patients, traditional markers of kidney function (urine output
      and serum Creatinine level) do not accurately represent renal function.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>renal biomarker levels</measure>
    <time_frame>through VA-ECMO decannulation, an average of 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>need for continuous renal replacement therapy at hospital discharge (Yes/No)</measure>
    <time_frame>measured at hospital discharge, an average of 2-3 months following initial hospital admission</time_frame>
    <description>The need for continuous renal replacement therapy at hospital discharge will be assessed using hospital medical records</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Kidney Injury</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biomarker levels</intervention_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine and blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with cardiogenic shock and acute kidney injury requiring continuous renal
        replacement therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age more than 18 years

          -  refractory or advanced cardiogenic shock prior to institution of VA-ECMO

        Exclusion Criteria:

          -  History of chronic kidney disease prior to cardiogenic shock, as defined by estimated
             glomerular filtration rate (GFR) less than 60 mL per min

          -  Cognitive impairment

          -  Pregnant women

          -  patient or surrogate is not fluent in English

          -  Long-term immunosuppression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diane McCloskey, PhD</last_name>
    <email>dmccloskey@hmc.psu.edu</email>
  </overall_contact>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 29, 2016</lastchanged_date>
  <firstreceived_date>November 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Anthony Bonavia</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
